(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid

We are (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid CAS:100564-78-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid
CAS.NO: 100564-78-1
Molecular Formula:C15H21NO4
Molecular Weight:279.33200

Synonyms:
2S-tert-butoxycarbonylamino-4-phenylbutyric acid
(2S)-2-({[(2-Methyl-2-propanyl)oxy]carbonyl}amino)-4-phenylbutanoic acid
(S)-2-(N-(tert-butoxycarbonyl)amino)-4-phenylbutanoic acid
(S)-Boc-homophenylalanine
(S)-2-(Boc-amino)-4-phenylbutyric Acid
N-Boc-L-homophenylalanine
Boc-Homophe-OH
N-Boc-D-Homophe-OH
Boc-HoPhe-OH
(2S)-2-[(tert-Butoxycarbonyl)amino]-4-phenylbutanoic acid
Boc-L-homophenylalanine
Boc-L-Homo-Phe
Benzenebutanoic acid, α-[[(1,1-dimethylethoxy)carbonyl]amino]-, (αS)-
N-(tert-butoxycarbonyl)-L-homophenylalanine
N-Boc-homophenylalanine
(S)-2-(tert-Butoxycarbonylamino)-4-phenylbutyric Acid
(S)-2-tert-butoxycarbonylamino-4-phenylbutyric acid

Physical and Chemical Properties:
Density: 1.139
Boiling point: 439.6ºC at 760mmHg
Melting point: 76-80ºC
Flash point: 219.7ºC
Refractive index: 1.524

Specification:
Appearance: white powder
Purity:≥99%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at 0-5ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Related News: In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.2-Iodo-1-ethanol acetate Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.129101-36-6 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).propano-1-tiol CAS:107-03-9 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.